YU Chunmei, ZHU Baofeng, PENG Qiang, QIN Guixiang. Application of pernasal high-flow oxygen therapy in treatment of severe pneumonia complicating with acute respiratory distress syndrome[J]. Journal of Clinical Medicine in Practice, 2021, 25(18): 20-23, 28. DOI: 10.7619/jcmp.20210515
Citation: YU Chunmei, ZHU Baofeng, PENG Qiang, QIN Guixiang. Application of pernasal high-flow oxygen therapy in treatment of severe pneumonia complicating with acute respiratory distress syndrome[J]. Journal of Clinical Medicine in Practice, 2021, 25(18): 20-23, 28. DOI: 10.7619/jcmp.20210515

Application of pernasal high-flow oxygen therapy in treatment of severe pneumonia complicating with acute respiratory distress syndrome

  •   Objective     To analyze application effect of high-flow nasal cannula oxygen therapy (HFNC) in patients with severe pneumonia (SP) complicating with acute respiratory distress syndrome (ARDS).
      Methods     A total of 90 SP patients with ARDS were selected as the study objects, and divided into experimental group (n=47) and control group (n=43) by random number table method. Both groups were given symptomatic treatment such as anti-infection, fluid resuscitation and nutritional support. The control group was treated with non-invasive ventilation, and the experimental group was treated with HFNC at the same time. After 1 week of treatment, sputum viscosity, blood gas index, comfort and tolerance, reintubation rate and complications were compared between the two groups.
      Results     The proportions of patients with sputum Ⅰ degree and Ⅱ degree in the experimental group was 95.74%, which was significantly higher than 81.40% in the control group (P < 0.05). Respiratory rate (RR) of the experimental group was significantly lower, arterial partial pressure of oxygenpa(O2), oxygen saturation (SaO2) and oxygenation indexpa(O2)/FiO2 of the experimental group were significantly higher than those of the control group (P < 0.05 or P < 0.01). The scores of comfort, dyspnea and tolerance of the experimental group were significantly lower than those of the control group (P < 0.01 or P < 0.05). The reintubation rate and the total incidence of complications in the experimental group were 6.38% and 8.51%, respectively, which were significantly lower than 23.26% and 25.58% in the control group (P < 0.05).
      Conclusion     HFNC can improve sputum viscosity and blood gas indexes in SP patients with ARDS, improve comfort and tolerance, and reduce the rate of reintubation and complication.
  • loading

Catalog

    Turn off MathJax
    Article Contents

    /

    DownLoad:  Full-Size Img  PowerPoint
    Return
    Return